Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s

Eli Lilly's Immunology division generated $2.6 billion in revenues in H1 2026, up 9% year-over-year, representing 6.1% of total revenues. Led by Taltz, the portfolio is expanding through newer products like Ebglyss and Omvoh, plus strategic acquisitions of DICE, Morphic, and Merida to strengthen its pipeline across IBD, autoimmune diseases, and allergies. However, the company faces intense competition from established players and newer therapies.